Available data support the safety and effectiveness of the Johnson & Johnson COVID-19 vaccine for emergency use authorization as a booster dose in individuals aged 18 and older at least two months after an initial single dose, the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 19-0 today. The committee also discussed early data from a study sponsored by the National Institute of Allergy and Infectious Diseases evaluating the immunogenicity of each of the three authorized COVID-19 vaccines following immunization with the same or a different booster dose.

The committee yesterday voted unanimously to recommend boosters for previous Moderna recipients age 65 and older, plus individuals age 18-64 if they are at high risk of severe COVID-19 or whose frequent institutional or occupational exposure puts them at high risk of serious complications, including severe COVID-19. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will consider the recommendations next week. FDA last month amended Pfizer’s emergency use authorization for its COVID-19 vaccine to allow for an additional, booster dose for certain individuals.

 

Related News Articles

Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…
Headline
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral…